Search

Search Constraints

You searched for: Author/Creator Do, Pascal

Search Results

1. Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04). (20th November 2019)

2. Economic Analysis of First‐Line Treatment with Erlotinib in anEGFR‐Mutated Population with Advanced NSCLC. Issue 6 (June 2016)

3. Utility of serum anti‐cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab. (24th October 2016)

4. Association between lung cancer somatic mutations and occupational exposure in never-smokers. Issue 4 (26th October 2017)

5. Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients. Issue 1 (13th February 2018)

6. Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting. Issue 2 (August 2015)

7. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non–small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. (September 2017)